Transcatheter pulmonary valve replacement is a significant advancement for treating stenotic or regurgitant valves in congenital heart disease patients, with ongoing efforts to extend it to native right ventricular outflow tracts.
May inform valve intervention choices in congenital heart disease; leaves open native RVOT durability and selection criteria.
Transcatheter pulmonary valve replacement is one of the most exciting recent developments in the treatment of patients with congenital heart disease and is being used to treat both stenotic and regurgitant valves within previously placed surgical conduits. Although limited somewhat by both patients and available valve sizes, ongoing attempts are being made to extend this technology to native right ventricular outflow tracts. If achieved, this will represent a significant advancement in attempts to prevent morbidity and mortality secondary to the chronic effects of right ventricular volume loading. This review deals with the development, current status and future endeavors of this approach.
No takes yet. Share an insight, caveat, or question.
Kenny et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: